Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort.
Sci Data
; 9(1): 405, 2022 07 13.
Article
in English
| MEDLINE | ID: covidwho-1931428
ABSTRACT
Worldwide, there are intensive efforts to identify repurposed drugs as potential therapies against SARS-CoV-2 infection and the associated COVID-19 disease. To date, the anti-inflammatory drug dexamethasone and (to a lesser extent) the RNA-polymerase inhibitor remdesivir have been shown to be effective in reducing mortality and patient time to recovery, respectively, in patients. Here, we report the results of a phenotypic screening campaign within an EU-funded project (H2020-EXSCALATE4COV) aimed at extending the repertoire of anti-COVID therapeutics through repurposing of available compounds and highlighting compounds with new mechanisms of action against viral infection. We screened 8702 molecules from different repurposing libraries, to reveal 110 compounds with an anti-cytopathic IC50 < 20 µM. From this group, 18 with a safety index greater than 2 are also marketed drugs, making them suitable for further study as potential therapies against COVID-19. Our result supports the idea that a systematic approach to repurposing is a valid strategy to accelerate the necessary drug discovery process.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19 Drug Treatment
Type of study:
Systematic review/Meta Analysis
Limits:
Humans
Language:
English
Journal:
Sci Data
Year:
2022
Document Type:
Article
Affiliation country:
S41597-022-01532-x
Similar
MEDLINE
...
LILACS
LIS